医学
二甲双胍
前列腺癌
内科学
肿瘤科
不利影响
癌症
前列腺
前列腺特异性抗原
临床试验
糖尿病
入射(几何)
梅德林
化疗
2型糖尿病
前列腺切除术
妇科
作者
Neil Eric Fleshner,Rui Miguel Marques Bernardino,Jonathan I. Izawa,Darrel Drachenberg,Jeff W. Saranchuk,Adrian Fairey,Simon Tanguay,Michael Leveridge,Fred Saad,Rodney Henry Breau,Bobby Shayegan,Laurence H. Klotz,Karen M. Hersey,Sunakshi Chowdhary,Karen R. Chadwick,Heidi E. Wagner,Tiiu Sildva,Shabbir M.H. Alibhai,Naghmeh Rastegar,Miran Kenk
摘要
PURPOSE Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progression. Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity in preclinical studies and observational data, prompting investigation into its potential to delay PCa progression. PATIENTS AND METHODS The Metformin Active Surveillance Trial (MAST) was a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of metformin in men with low-risk, localized PCa managed with AS. Eligible participants were randomly assigned 1:1 to receive either metformin (850 mg twice daily) or placebo and were followed for up to 36 months. The primary end point was time to progression, defined as therapeutic and/or pathologic progression. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS A total of 408 patients were randomly assigned (205 metformin, 203 placebo). After a median follow-up of 36 months, 144 participants experienced progression (70 metformin, 74 placebo), with no significant difference in PFS (hazard ratio [HR], 1.09 [95% CI, 0.79 to 1.52]; P = .59). Negative biopsy rates at 36 months were 41.0% (metformin) versus 31.1% (placebo; P = .181). In prespecified subgroup analysis, metformin was associated with increased pathologic progression among obese patients (BMI ≥ 30; HR, 2.36 [95% CI, 1.21 to 4.59]; P = .0092). CONCLUSION Metformin did not reduce progression in men with low-risk PCa on AS. The observed adverse effect in obese patients merits further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI